MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Bratcher, Preston E ^a   Weathington, Nathaniel M ^b   Nick, Heidi J ^a   Jackson, Patricia L ^a   Snelgrove, Robert J ^c   Gaggar, Amit ^a,d,e,f  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GELATINASE B; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN; SURFACTANT PROTEIN D;

ANIMAL CELL; ARTICLE; BACTERIAL CLEARANCE; BINDING ASSAY; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN INTERACTION; SOLID PHASE SYNTHESIS;

ANIMALS; CALCIUM; CELL LINE; ESCHERICHIA COLI; HUMANS; IMMUNITY, INNATE; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MATRIX METALLOPROTEINASE 9; MICE; PHAGOCYTOSIS; PROTEIN BINDING; PROTEOLYSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 84864437966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041881     Document Type: Article

References (51)

1. Atkinson JJ, Senior RM, ((2003)) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28:: 12--24.
2. Cauwe B, Van den Steen PE, Opdenakker G, ((2007)) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42:: 113--185.
3. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G, ((2000)) Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96:: 2673--2681.
4. Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, et al. ((2008)) Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 7:: 2215--2228.
5. Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, et al. ((1996)) Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 271:: 14657--14660.
6. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL, ((1985)) Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 260:: 2493--2500.
7. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, et al. ((2002)) The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 41:: 9462--9469.
8. Visse R, Nagase H, ((2003)) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:: 827--839.
9. Louhelainen N, Stark H, Mazur W, Rytila P, Djukanovic R, et al. ((2010)) Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study. BMC Pulm Med 10:: 13.
10. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, et al. ((2009)) Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 103:: 1231--1238.
11. Beeh KM, Beier J, Kornmann O, Buhl R, ((2003)) Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 97:: 634--639.
12. Boulay ME, Prince P, Deschesnes F, Chakir J, Boulet LP, ((2004)) Metalloproteinase-9 in induced sputum correlates with the severity of the late allergen-induced asthmatic response. Respiration 71:: 216--224.
13. Oshita Y, Koga T, Kamimura T, Matsuo K, Rikimaru T, et al. ((2003)) Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax 58:: 757--760.
14. Cataldo DD, Bettiol J, Noel A, Bartsch P, Foidart JM, et al. ((2002)) Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 122:: 1553--1559.
15. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, et al. ((2006)) Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 61:: 1037--1042.
16. Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T, et al. ((2002)) Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J 20:: 1220--1227.
17. Gaggar A, Li Y, Weathington N, Winkler M, Kong M, et al. ((2007)) Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293:: L96--L104.
18. Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, et al. ((2009)) Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation. J Cyst Fibros 8:: 338--347.
19. Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, et al. ((2003)) Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 31:: 536--542.
20. El-Solh AA, Amsterdam D, Alhajhusain A, Akinnusi ME, Saliba RG, et al. ((2009)) Matrix metalloproteases in bronchoalveolar lavage fluid of patients with type III Pseudomonas aeruginosa pneumonia. J Infect 59:: 49--55.
21. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z, ((2002)) Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 6:: 713--719.
22. Bergin PJ, Anders E, Sicheng W, Erik J, Jennie A, et al. ((2004)) Increased production of matrix metalloproteinases in Helicobacter pylori-associated human gastritis. Helicobacter 9:: 201--210.
23. Tsai HC, Liu SF, Wu KS, Liu YC, Shi MH, et al. ((2008)) Dynamic changes of matrix metalloproteinase-9 in patients with Klebsiella pneumoniae meningitis. Inflammation 31:: 247--253.
24. Bottcher T, Spreer A, Azeh I, Nau R, Gerber J, ((2003)) Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett 338:: 201--204.
25. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Lijnen HR, et al. ((2006)) Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 176:: 3735--3741.
26. Malik M, Bakshi CS, McCabe K, Catlett SV, Shah A, et al. ((2007)) Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J Immunol 178:: 1013--1020.
27. Imtiaz MT, Distelhorst JT, Schripsema JH, Sigar IM, Kasimos JN, et al. ((2007)) A role for matrix metalloproteinase-9 in pathogenesis of urogenital Chlamydia muridarum infection in mice. Microbes Infect 9:: 1561--1566.
28. Hartl D, Griese M, ((2006)) Surfactant protein D in human lung diseases. Eur J Clin Invest 36:: 423--435.
29. Kingma PS, Whitsett JA, ((2006)) In defense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol. 6:: 277--283.
30. Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, et al. ((2006)) Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 43:: 1293--1315.
31. Erpenbeck VJ, Schmidt R, Gunther A, Krug N, Hohlfeld JM, ((2006)) Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma. Allergy 61:: 598--604.
32. Sin DD, Man SF, McWilliams A, Lam S, ((2008)) Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest 134:: 582--588.
33. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S, ((1996)) Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 109:: 1006--1009.
34. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, et al. ((2009)) Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 34:: 95--102.
35. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, et al. ((2000)) Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162:: 1109--1114.
36. Olesen HV, Holmskov U, Schiotz PO, Sorensen GL, ((2010)) Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis. J Cyst Fibros 9:: 257--262.
37. Jounblat R, Clark H, Eggleton P, Hawgood S, Andrew PW, et al. ((2005)) The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia. Respir Res 6:: 126.
38. Giannoni E, Sawa T, Allen L, Wiener-Kronish J, Hawgood S, ((2006)) Surfactant proteins A and D enhance pulmonary clearance of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 34:: 704--710.
39. Atochina EN, Gow AJ, Beck JM, Haczku A, Inch A, et al. ((2004)) Delayed clearance of pneumocystis carinii infection, increased inflammation, and altered nitric oxide metabolism in lungs of surfactant protein-D knockout mice. J Infect Dis 189:: 1528--1539.
40. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR, ((2001)) Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 167:: 5868--5873.
41. LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, et al. ((2004)) Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 31:: 193--199.
42. Madan T, Reid KB, Clark H, Singh M, Nayak A, et al. ((2010)) Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol 47:: 1923--1930.
43. Griese M, Wiesener A, Lottspeich F, von Bredow C, ((2003)) Limited proteolysis of surfactant protein D causes a loss of its calcium-dependent lectin functions. Biochim Biophys Acta 1638:: 157--163.
44. Hirche TO, Crouch EC, Espinola M, Brokelman TJ, Mecham RP, et al. ((2004)) Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. J Biol Chem 279:: 27688--27698.
45. Alcorn JF, Wright JR, ((2004)) Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol Chem 279:: 30871--30879.
46. Cooley J, McDonald B, Accurso FJ, Crouch EC, Remold-O'Donnell E, ((2008)) Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease. J Leukoc Biol 83:: 946--955.
47. Duvoix A, Mackay RM, Henderson N, McGreal E, Postle A, et al. ((2011)) Physiological concentration of calcium inhibits elastase-induced cleavage of a functional recombinant fragment of surfactant protein D. Immunobiology. 216:: 72--79.
48. Yoshida M, Korfhagen TR, Whitsett JA, ((2001)) Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol 166:: 7514--7519.
49. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, et al. ((2011)) The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 38:: 721--727.
50. Kuan SF, Rust K, Crouch E, ((1992)) Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 90:: 97--106.
51. Davidson J, Kerr A, Guy K, Rotondo D, ((1998)) Prostaglandin and fatty acid modulation of Escherichia coli O157 phagocytosis by human monocytic cells. Immunology 94:: 228--234.